Romiplostim Dosing Protocol for ITP Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic immune thrombocytopenia (ITP) often require long-term medication and have adverse effects, with limited predictors for achieving durable remission, making it challenging to manage the condition effectively.
Innovation Solution
Administering romiplostim weekly to achieve and maintain a platelet count of 50-200×10^9/L, then adjusting the dose based on platelet levels, with the goal of discontinuing treatment if platelet counts remain elevated, allowing for a treatment-free period of at least 24 weeks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments (corticosteroids, immunoglobulins, immunosuppressive agents) are used to treat chronic ITP, then platelet counts can be improved, but adverse effects and compliance issues arise with long-term treatment
Solution Approach 1:
The patent applies parameter changes by transitioning from traditional treatments (corticosteroids, immunoglobulins) to romiplostim, a TPO receptor agonist with a different mechanism of action. This parameter change in treatment modality achieves sustained platelet count improvement while reducing adverse effects associated with long-term use of conventional therapies.
2Duration of action of stationary object
If long-term treatment with romiplostim is required to maintain platelet responses, then durable improvement in platelet counts is achieved, but compliance issues and substantial costs increase
Solution Approach 1:
The patent implements feedback by using platelet count monitoring to guide treatment decisions. Patients who achieve sustained platelet responses (≥50×10^9/L) for specific durations can have their treatment interrupted or discontinued, allowing the body to maintain responses through endogenous TPO stimulation. This feedback mechanism reduces long-term compliance burden while maintaining durable platelet improvement.
3Reliability
If treatment is continued indefinitely to maintain platelet counts, then bleeding risk is reduced, but treatment burden and costs increase
Solution Approach 1:
The patent applies preliminary action by establishing a treatment protocol where romiplostim is administered for a defined initial period to induce and sustain platelet responses. Once platelet counts are maintained above threshold levels for specified durations, treatment can be interrupted, allowing the therapeutic effect to persist without continuous administration. This preliminary treatment phase reduces long-term treatment burden while maintaining bleeding protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows approximately one-quarter of patients to discontinue ITP treatments while maintaining hemostatic platelet counts, reducing bleeding incidents and the use of other medications, with a safety profile similar to that in adults, and identifying platelet count within the first 4-12 weeks as a predictor for remission.
Implementation Method 1
Romiplostim is a thrombopoietin (TPO) receptor agonist that has been shown to increase and sustain platelet counts
Data Source
AI summary
The present invention concerns a method of treating idiopathic thrombocytopenia purpura (ITP) in a patient having ITP, which comprises: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least about 50 to 200×109/L is reached; (c) decreasing the weekly dose of romiplostim if the platelet count remains ≥200×109/L for two consecutive weeks; (d) discontinuing romiplostim if the platelet count has remained ≥200×109/L for two consecutive weeks when the weekly dose is 1 μg/kg or the platelet count is ≥400×109/L; and (e) if a platelet count ≥200×109/L is reached within the first 4 to 12 weeks of treatment, maintaining a treatment-free period of at least about 24 weeks during which the patient receives no romiplostim.